📰 Advanced Solid Tumors News
Page 2 - Advanced Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.
January 30, 2024
Phase 2 trial investigators hope denifanstat can be a key component in restoring sensitivity to HER2- positive metastatic breast cancer treatments.
January 24, 2024
KVA12123 demonstrated early signals of on-target activity and tolerability at all dose levels examined to date in patients with advanced solid tumors.
December 22, 2023
- Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200- - Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300-- Received FDA feedback on TYRA-300...
December 13, 2023
Company to also share progress with cell-based virotherapy platforms for advanced solid tumors ...
December 5, 2023
The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug ...
October 18, 2023
Russell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.
September 28, 2023
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
September 28, 2023
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate
September 27, 2023
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
September 27, 2023
WALTHAM, Mass., Sept. 27, 2023 -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with...